Showing 1-10 of about 16 articles.
Equillium
LA JOLLA, Calif., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company developing treatments for severe immuno-inflammatory disorders, today announced that the...
PledPharma AB
Stockholm, December 24, 2018. PledPharma AB (publ) announces that the company has filed an application for an Orphan Drug Designation (ODD) to the US FDA for the drug candidate Aladote®, developed to...
PledPharma AB
Stockholm, 24 december 2018. PledPharma AB (publ) meddelar att bolaget har lämnat in en ansökan till amerikanska läkemedelsmyndigheten FDA om särläkemedelsstatus (ODD, Orphan Drug Designation) för...
Akari Therapeutics, Plc
NEW YORK and LONDON, Jan. 03, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that the U.S. Food and Drug...
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, Dec. 14, 2016 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX) (the “Company”) announced today that the Company received a letter from Fundação Oswaldo...
Akari Therapeutics, Plc
-Phase Ib cohorts demonstrate dose effect and additional support for once daily dosing--PAS-Coversin pre-clinical data supports once weekly dosing--Phase II PNH patients identified with data expected...
Akari Therapeutics, Plc
NEW YORK and LONDON, Sept. 12, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, development-stage biopharmaceutical company, announced today that the U.S. Food and...
Akari Therapeutics, Plc
NEW YORK and LONDON, July 13, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today the approval by the UK...
XOMA Corporation
BERKELEY, Calif., June 28, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today it has initiated its Phase...
Akari Therapeutics Plc
NEW YORK and LONDON, May 23, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that the European Medicines...
Showing 1-10 of about 16 articles.
